Abstract: The present invention provides methods of treating mycobacterial infections or mycobacterial diseases by administering a tetracycline compound, e.g., omadacycline, or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
September 3, 2019
Date of Patent:
December 10, 2024
Assignees:
Paratek Pharmaceuticals, Inc., The United States Government as represented by the Department of Veterans Affairs
Inventors:
Michael Henry Cynamon, Michael P. Draper, Judith N. Steenbergen, S. Ken Tanaka
Abstract: Methods of treating or preventing a bacterial infection in a subject are disclosed herein, wherein the bacterial infection is caused by a bacterium which can be used as a biological weapon. Also disclosed is a pharmaceutical composition comprising the compound of the present invention for treating or preventing a bacterial infection in a subject, wherein the bacterial infection is caused by a bacterium which can be used as a biological weapon.
Abstract: The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
Type:
Application
Filed:
November 4, 2020
Publication date:
February 25, 2021
Applicants:
Paratek Pharmaceuticals, Inc., Paratek Pharmaceuticals, Inc.
Inventors:
Evangelos L. Tzanis, Paul McGovern, Amy L. Manley, Lynne Garrity-Ryan, S. Ken Tanaka
Abstract: The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
Type:
Grant
Filed:
July 10, 2019
Date of Patent:
November 17, 2020
Assignee:
Paratek Pharmaceuticals, Inc.
Inventors:
Evangelos L. Tzanis, Paul McGovern, Amy L. Manley, Lynne Garrity-Ryan, S. Ken Tanaka
Abstract: The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
Type:
Grant
Filed:
October 31, 2017
Date of Patent:
August 20, 2019
Assignee:
Paratek Pharmaceuticals, Inc.
Inventors:
Evangelos L. Tzanis, Paul McGovern, Amy L. Manley, Lynne Garrity-Ryan, S. Ken Tanaka
Abstract: The invention disclosed herein provides a method for treating urinary tract infection (UTI) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
Type:
Grant
Filed:
May 2, 2017
Date of Patent:
March 26, 2019
Assignee:
Paratek Pharmaceuticals, Inc.
Inventors:
Amy L. Manley, Evangelos L. Tzanis, Lynne Garrity-Ryan, S. Ken Tanaka, Judith N. Steenbergen, Stephen Bai
Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans Streptococci, Enterococcus, or combinations thereof.
Type:
Grant
Filed:
June 29, 2017
Date of Patent:
November 13, 2018
Assignee:
Paratek Pharmaceuticals, Inc.
Inventors:
Sean M. Johnston, Robert D. Arbeit, Thomas J. Bigger, Dennis P. Molnar, S. Ken Tanaka
Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein the 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days.
Type:
Grant
Filed:
August 3, 2017
Date of Patent:
October 30, 2018
Assignee:
Paratek Pharmaceuticals, Inc.
Inventors:
S. Ken Tanaka, Evangelos L. Tzanis, Lynne Garrity-Ryan, Amy L. Manley
Abstract: The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
Abstract: The present invention provides liquid dosage forms for treating narcolepsy. The liquid dosage form includes zolpidem or a pharmaceutically acceptable salt thereof, a carbonate salt, a citrate salt, and a phosphate salt. The present invention also provides methods for treating somnambulism. The methods include administering an emulsion that includes zolpidem, a bicarbonate salt, a metal oxide, and a borate salt.
Type:
Application
Filed:
March 30, 2017
Publication date:
March 22, 2018
Applicant:
PARATEK PHARMACEUTICALS, INC.
Inventors:
Nikhilesh N. Singh, Sathasivan I. Pather
Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein the 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline is administered orally at a dose of about 450 mg per day for two consecutive days, then at a dose of about 300 mg per day for 5 or more days.
Type:
Application
Filed:
August 3, 2017
Publication date:
March 1, 2018
Applicant:
Paratek Pharmaceuticals, Inc.
Inventors:
S. Ken Tanaka, Evangelos L. Tzanis, Lynne Garrity-Ryan, Amy L. Manley
Abstract: The invention disclosed herein provides a method for treating urinary tract infection (UTI) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
Type:
Application
Filed:
May 2, 2017
Publication date:
November 23, 2017
Applicant:
Paratek Pharmaceuticals, Inc.
Inventors:
Amy L. Manley, Evangelos L. Tzanis, Lynne Garrity-Ryan, S. Ken Tanaka
Abstract: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans Streptococci, Enterococcus, or combinations thereof.
Type:
Grant
Filed:
February 2, 2016
Date of Patent:
August 8, 2017
Assignee:
Paratek Pharmaceuticals, Inc.
Inventors:
Sean M. Johnston, Robert D. Arbeit, Thomas J. Bigger, Dennis P. Molnar, S. Ken Tanaka
Abstract: The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter-subject variability. Furthermore, delivery of the hypnotic agent across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. Methods for using the compositions of the present inversion for treating sleep disorders such as insomnia are also provided.
Abstract: The present invention pertains, at least in part, to novel substituted etracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.